Clinical and Biochemical Characterization of Hereditary ATTR Amyloidosis Caused by a Novel Transthyretin Variant V121A (p.V141A)
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26104659 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Tsuneaki Yoshinaga und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Health Care Science Institute, Health, Labour and Welfare SciencesResearch.
Abstract (Originalsprache)
Over 150 transthyretin (TTR) mutations have been identified in hereditary transthyretin (ATTRv) amyloidosis, and new TTR variants have recently emerged. However, the pathogenicity of several new variants remains unclear, making it important to elucidate the differences between amyloidogenic and wild-type TTR. In this study, we report a novel TTR variant (V121A) identified in two unrelated amyloidosis patients aged > 60 years who developed cardiomyopathy. We evaluated the detailed biochemical features of this TTR variant to confirm its amyloidogenicity using plasma samples from these patients and recombinant TTR proteins. While the V121A TTR variant has a similar ability to assemble into a tetramer as wild-type TTR, it aggregates more readily over a wide potential hydrogen range than wild-type TTR. Additionally, the V121A variant is highly prone to dissociation and resistant to binding with known TTR tetramer stabilizers. Clinical and biochemical data suggest that this novel variant is clearly pathogenic, is highly prone to dissociation and aggregation, and is associated with the development of late-onset amyloid cardiomyopathy. Interestingly, amyloid fibril formation due to this variant may not be affected by known TTR stabilizers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
- Department of Neurology and Rheumatology, Shinshu University, Matsumoto 390-8621, Japan.
- Institute for Biomedical Sciences, Shinshu University, Matsumoto 390-8621, Japan.
- Department of Nephrology, Tachikawa General Hospital, Nagaoka 940-0831, Japan.
- Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.
- Department of Cardiology, Tachikawa General Hospital, Nagaoka 940-0831, Japan.
ORCID-Profile: Felix J Tsai, Ming Cheng, Fuyuki Kametani, Takahiro Okumura, Masahide Yazaki
Förderung
- The Health Care Science Institute
- Health, Labour and Welfare SciencesResearch
Zitieren
APA
Yoshinaga, T., Yoshioka, Y., Tsai, F. J., Nelson, L., Cheng, M., Ito, R., Fujita, S., Ishikawa, E., Kametani, F., Aoyagi, R., Okumura, T., Murohara, T., Yazaki, M., & Sekijima, Y. (2025). Clinical and Biochemical Characterization of Hereditary ATTR Amyloidosis Caused by a Novel Transthyretin Variant V121A (p.V141A). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104659
Vancouver
Yoshinaga T, Yoshioka Y, Tsai FJ, Nelson L, Cheng M, Ito R, et al. Clinical and Biochemical Characterization of Hereditary ATTR Amyloidosis Caused by a Novel Transthyretin Variant V121A (p.V141A). International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104659
BibTeX
@article{Yoshinaga2025,
author = {Yoshinaga, Tsuneaki and Yoshioka, Yuuki and Tsai, Felix J and Nelson, Luke and Cheng, Ming and Ito, Ryota and Fujita, Satoshi and Ishikawa, Eri and Kametani, Fuyuki and Aoyagi, Ryuzi and Okumura, Takahiro and Murohara, Toyoaki and Yazaki, Masahide and Sekijima, Yoshiki},
title = {Clinical and Biochemical Characterization of Hereditary ATTR Amyloidosis Caused by a Novel Transthyretin Variant V121A (p.V141A)},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26104659}
}
EUVIMED